Welcome to our dedicated page for CNS Pharmaceuticals SEC filings (Ticker: CNSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CNS Pharmaceuticals, Inc. (CNSP) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. CNS Pharmaceuticals is a clinical-stage biopharmaceutical company whose common stock trades on The Nasdaq Stock Market LLC under the symbol CNSP, as noted in its current reports on Form 8-K.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed information on CNS Pharmaceuticals’ financial condition, risk factors, and discussion of its clinical-stage pipeline of anti-cancer drug candidates for brain and central nervous system tumors. These periodic reports complement the company’s press releases describing its lead candidate TPI 287, an abeotaxane with initial clinical data suggesting potential to cross the blood-brain barrier and treat CNS tumors.
The filings feed also includes current reports on Form 8-K that document material events. Recent 8-K filings describe a leadership transition in which the company entered into an employment agreement with Rami Levin to serve as Chief Executive Officer and President, the resignation and severance arrangements for former CEO John Climaco, and stockholder-approved changes to the company’s capital structure, including amendments to its articles of incorporation and 2020 Equity Plan.
Investors can also use this page to track proxy materials such as the definitive proxy statement on Schedule 14A, which outlines proposals presented at the annual meeting, including election of directors, auditor ratification, advisory votes on executive compensation, and increases in authorized share capital. Stock Titan enhances these documents with AI-powered summaries that highlight key points, helping users quickly understand complex filings, from governance decisions to equity plan amendments, while retaining the ability to read the full original SEC text.
CNS Pharmaceuticals, Inc. reported results of its 2025 annual stockholder meeting and related corporate changes. Stockholders approved an amendment to the company’s Amended and Restated Articles of Incorporation to increase authorized common stock from 25,000,000 shares to 300,000,000 shares and authorized preferred stock from 416,667 shares to 5,000,000 shares, and the company filed the amendment in Nevada to make these changes effective. They also approved amendments to the 2020 Equity Plan, raising the number of shares of common stock that may be issued under the plan to 115,061 shares.
All director nominees were elected to serve until the 2026 annual meeting, the appointment of MaloneBailey, LLP as independent auditor for the year ending December 31, 2025 was ratified, and executive compensation was approved on an advisory basis. Stockholders recommended holding the advisory say‑on‑pay vote every year, and the board chose an annual frequency in line with that recommendation. As of the October 10, 2025 record date, 574,580 shares of common stock were issued and outstanding, with 204,107 shares represented at the meeting, constituting a quorum.
CNS Pharmaceuticals, Inc. (CNSP) reported a Form 4 showing a director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share. The option was originally approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan, which shareholders granted on November 17, 2025. The option becomes exercisable in four equal quarterly installments starting on the November 17, 2025 shareholder approval date, as long as the director continues in employment on each vesting date, and expires on November 17, 2035. The filing states the option was issued in connection with the reporting person’s employment and is held as a direct ownership position.
CNS Pharmaceuticals, Inc. (CNSP) reported a Form 4 filing for a director covering a new stock option grant. The derivative security is an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, expiring on November 17, 2035.
The grant was approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, defined as the “Shareholder Approval Date.” The options vest in four equal quarterly installments starting on the Shareholder Approval Date, contingent on the reporting person’s continued employment. After this transaction, the reporting person beneficially owns 1,517 derivative securities directly.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to its chief executive officer and director on a Form 4. The filing shows an option to purchase 9,761 shares of common stock at an exercise price of $30 per share, dated 11/17/2025 and expiring on 11/17/2035.
The option was originally approved on 03/11/2025, subject to shareholder approval of the stock option plan, which was obtained on 11/17/2025. The grant vests over 18 months: 50% on the six‑month anniversary of the grant date, 25% on the 12‑month anniversary, and 25% on the 18‑month anniversary, conditioned on continued employment. The reporting person beneficially owns 9,761 derivative securities directly after this transaction.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant on a Form 4 for a director. The filing shows an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, approved by the compensation committee on June 6, 2025 and made effective upon shareholder approval on November 17, 2025. The option vests in four equal quarterly installments beginning on the shareholder approval date, contingent on continued employment at each vesting date, and carries an expiration date of November 17, 2035. The option was issued in connection with the reporting person’s employment with the company.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to a director on a Form 4. The filing shows an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, dated 11/17/2025 with an expiration date of 11/17/2035.
The grant was originally approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, which is also the “Shareholder Approval Date.” The options vest in four equal quarterly installments starting on that approval date, conditioned on the director’s continued service with the company.
CNS Pharmaceuticals, Inc. reported an equity compensation grant to its Chief Financial Officer, Christopher Downs, on a Form 4. The filing shows an option to purchase 4,881 shares of common stock at a conversion or exercise price of $30 per share, with no price paid for the option itself. The option was approved by the compensation committee on the March 11, 2025 grant date, subject to shareholder approval of the stock option plan.
CNS Pharmaceuticals’ shareholders approved the plan at the annual meeting on November 17, 2025, making the grant effective. The options vest over 18 months, with 50% vesting on the six-month anniversary of the grant date, 25% on the 12-month anniversary, and 25% on the 18-month anniversary, conditioned on the CFO’s continued employment with the company.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to one of its directors on Form 4. On November 17, 2025, the director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, with an expiration date of November 17, 2035.
The option was originally approved by the compensation committee on June 6, 2025, and became effective after shareholders approved the underlying stock option plan on November 17, 2025, described as the Shareholder Approval Date. The options vest in four equal quarterly installments starting on that approval date, conditioned on the director’s continued employment with the company. The filing notes that the option was issued in connection with the reporting person’s employment and is held as a direct ownership position.
CNS Pharmaceuticals reported Q3 2025 results with a narrower net loss of $3,218,481 versus $5,605,934 a year ago, as operating expenses fell to $3,253,388 from $5,628,906. General and administrative costs were $1,056,560, and research and development was $2,196,828, reflecting lower Berubicin trial spend and prior-year TPI 287 in‑licensing costs.
For the nine months, net loss improved to $9,894,762 from $11,681,435. Cash and equivalents were $9,864,087 with working capital of about $9,447,000. The company raised capital through an AGP at‑the‑market program—127,582 shares for roughly $9.0M in Q1–Q3 2025 (cumulative 210,230 shares for about $22.8M through Sept 30)—and a May 2025 public offering yielding net proceeds of about $4.5M. Management states substantial doubt about continuing as a going concern, while estimating current liquidity could extend operations into the second half of 2026, subject to clinical timelines and additional financing needs.